Phase III Trial of FOLFOX plus Bevacizumab or Cediranib (AZD2171) as First-Line Treatment of Patients with Metastatic Colorectal Cancer: HORIZON III

被引：40

作者：

Robertson, Jane D. ^{[1
]}

Botwood, Nick A. ^{[1
]}

Rothenberg, Mace L. ^{[2
]}

Schmoll, Hans-Joachim ^{[3
]}

机构：

[1] AstraZeneca, Macclesfield, Cheshire, England

[2] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[3] Univ Halle Wittenberg, Halle, Germany

来源：

CLINICAL COLORECTAL CANCER | 2009年 / 8卷 / 01期

关键词：

5-Fluorouracil; Leucovorin; Oxaliplatin; VEGF signaling inhibitor;

D O I：

10.3816/CCC.2009.n.010

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Cediranib is a highly potent and selective inhibitor of the 3 vascular endothelial growth factor receptors and has a half-life suitable for once-daily oral dosing. It is currently in phase III development for the first-line treatment of metastatic colorectal cancer. This article summarizes the clinical development program, which includes 2 global phase III studies, HORIZON II and HORIZON III, in the first-line treatment setting and a phase II study in second-line treatment (HORIZON I).

引用

页码：59 / 60

页数：2

共 50 条

[21] AZD2171 (Cediranib) is active in first line metastatic renal cell carcinoma (RCC): Interim results of a phase II trial. A trial of the PMH Phase II Consortium
Sridhar, Srikala S.
Mackenzie, Mary J.
Hotte, Sebastien J.
Mukherjee, Som D.
Murray, Nevin
Tannock, Ian F.
Haider, Masoom A.
Chen, Eric X.
Wang, Lisa
Srinivasan, Ranuka
Ivy, S. Percy
Moore, Malcolm J.
[J]. MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3337S - 3338S
[22] Phase Ib study of drozitumab combined with first-line FOLFOX plus bevacizumab (BV) in patients (pts) with metastatic colorectal cancer (mCRC).
Lima, C. S. Rocha
Baranda, J. C.
Wallmark, J.
Choi, Y.
Royer-Joo, S.
Portera, C. C.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
[23] FOLFOXIRI PLUS BEVACIZUMAB AS FIRST-LINE TREATMENT OF BRAF MUTANT METASTATIC COLORECTAL CANCER PATIENTS
Salvatore, Lisa
Loupakis, Fotios
Cremolini, Chiara
Schirripa, Marta
Masi, Gianluca
Antoniotti, Carlotta
Fornaro, Lorenzo
Sensi, Elisa
Lupi, Cristiana
Bergamo, Francesca
Lonardi, Sara
Zagonel, Vittorina
Fontanini, Gabriella
Falcone, Alfredo
[J]. ANNALS OF ONCOLOGY, 2012, 23 : 93 - 93
[24] Patients with Metastatic Colorectal Cancer and Hyperbilirubinemia Treated with FOLFIRI plus Bevacizumab as First-Line Treatment
Huang, Ching-Wen
Yeh, Yung-Sung
Ma, Cheng-Jen
Tsai, Hsiang-Lin
Chen, Chao-Wen
Huang, Ming-Yii
Lu, Chien-Yu
Wu, Jeng-Yih
Wang, Jaw Yuan
[J]. CHEMOTHERAPY, 2017, 62 (01) : 80 - 84
[25] Bevacizumab plus XELOX as first-line therapy for patients with metastatic colorectal cancer
Gaspar, E.
Juarez Marroqui, A.
Vicent, J.
Llorca, C.
Orts, D.
Galan, A.
Barrajon, E.
Cervera Grau, J.
Giner, V.
Macia, S.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[26] A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer
Bendell, Johanna C.
Hochster, Howard
Hart, Lowell L.
Firdaus, Irfan
Mace, Joseph R.
McFarlane, Joshua J.
Kozloff, Mark
Catenacci, Daniel
Hsu, Jessie J.
Hack, Stephen P.
Shames, David S.
Phan, See-Chun
Koeppen, Hartmut
Cohn, Allen L.
[J]. ONCOLOGIST, 2017, 22 (03): : 264 - 271
[27] PRESPECIFIED SUBGROUP ANALYSES IN WJOG4407G TRIAL, A RANDOMIZED PHASE III TRIAL OF MFOLFOX6 PLUS BEVACIZUMAB VERSUS FOLFIRI PLUS BEVACIZUMAB IN FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER
Hiroshi, Tamagawa
Kentaro, Yamazaki
Koichi, Suyama
Michio, Okabe
Kazuya, Suzuki
Nobuhiko, Seki
Kentaro, Kawakami
Mikio, Sato
Yasuo, Takahashi
Tomonori, Hirashima
Masahide, Ebi
Keisei, Taku
Toshio, Otsuji
Fumio, Tamura
Eiji, Shinozaki
Koji, Nakashima
Kensei, Yamaguchi
Masahiko, Ando
Satoshi, Morita
Narikazu, Boku
Ichinosuke, Hyodo
[J]. ANNALS OF ONCOLOGY, 2014, 25
[28] A phase III trial of exemestane plus bevacizumab maintenance therapy in patients with metastatic breast cancer after first-line taxane and bevacizumab: a GINECO group study
Tredan, O.
Follana, P.
Moullet, I.
Cropet, C.
Trager-Maury, S.
Dauba, J.
Lavau-Denes, S.
Dieras, V.
Beal-Ardisson, D.
Gouttebel, M.
Orfeuvre, H.
Stefani, L.
Jouannaud, C.
Burki, F.
Petit, T.
Guardiola, E.
Becuwe, C.
Blot, E.
Pujade-Lauraine, E.
Bachelot, T.
[J]. ANNALS OF ONCOLOGY, 2016, 27 (06) : 1020 - 1029
[29] First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD Study
Diaz-Rubio, Eduardo
Gomez-Espana, Auxiliadora
Massuti, Bartomeu
Sastre, Javier
Abad, Albert
Valladares, Manuel
Rivera, Fernando
Safont, Maria J.
Martinez de Prado, Purificacion
Gallen, Manuel
Gonzalez, Encarnacion
Marcuello, Eugenio
Benavides, Manuel
Fernandez-Martos, Carlos
Losa, Ferran
Escudero, Pilar
Arrivi, Antonio
Cervantes, Andres
Duenas, Rosario
Lopez-Ladron, Amelia
Lacasta, Adelaida
Llanos, Marta
Tabernero, Jose M.
Anton, Antonio
Aranda, Enrique
[J]. ONCOLOGIST, 2012, 17 (01): : 15 - 25
[30] Induction treatment in first-line with chemotherapy plus bevacizumab (bev) in metastatic colorectal cancer: Results from the gercor-DREAM phase III study
Tournigand, Christophe
Scheithauer, Werner
Samson, Benoit
Lledo, Gerard
Viret, Frederic
Andre, Thierry
Ramee, Jean Francois
Tubiana-Mathieu, Nicole
Dauba, Jerome
Dupuis, Olivier
Rinaldi, Yves
Mabro, May
Aucoin, Nathalie
Khalil, Ahmed
Latreille, Jean
Louvet, Christophe
Brusquant, David
Bonnetain, Franck
Chibaudel, Benoist
De Gramont, Aimery
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)

← 1 2 3 4 5 →